496 related articles for article (PubMed ID: 19845698)
1. Voriconazole concentrations and outcome of invasive fungal infections.
Miyakis S; van Hal SJ; Ray J; Marriott D
Clin Microbiol Infect; 2010 Jul; 16(7):927-33. PubMed ID: 19845698
[TBL] [Abstract][Full Text] [Related]
2. Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory.
Miyakis S; van Hal SJ; Solvag CJ; Ray J; Marriott D
Ther Drug Monit; 2010 Oct; 32(5):661-4. PubMed ID: 20720520
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
[TBL] [Abstract][Full Text] [Related]
5. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
Howard A; Hoffman J; Sheth A
Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
[TBL] [Abstract][Full Text] [Related]
6. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
[TBL] [Abstract][Full Text] [Related]
7. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency.
Gerin M; Mahlaoui N; Elie C; Lanternier F; Bougnoux ME; Blanche S; Lortholary O; Jullien V
Ther Drug Monit; 2011 Aug; 33(4):464-6. PubMed ID: 21743382
[TBL] [Abstract][Full Text] [Related]
9. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity.
Suzuki Y; Tokimatsu I; Sato Y; Kawasaki K; Sato Y; Goto T; Hashinaga K; Itoh H; Hiramatsu K; Kadota J
Clin Chim Acta; 2013 Sep; 424():119-22. PubMed ID: 23747486
[TBL] [Abstract][Full Text] [Related]
10. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
[TBL] [Abstract][Full Text] [Related]
11. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
Marty FM; Lowry CM; Cutler CS; Campbell BJ; Fiumara K; Baden LR; Antin JH
Biol Blood Marrow Transplant; 2006 May; 12(5):552-9. PubMed ID: 16635790
[TBL] [Abstract][Full Text] [Related]
12. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
Przepiorka D; Buadi FK; McClune B
Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
[TBL] [Abstract][Full Text] [Related]
13. Adverse reactions to voriconazole.
Boyd AE; Modi S; Howard SJ; Moore CB; Keevil BG; Denning DW
Clin Infect Dis; 2004 Oct; 39(8):1241-4. PubMed ID: 15486850
[TBL] [Abstract][Full Text] [Related]
14. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.
Park WB; Kim NH; Kim KH; Lee SH; Nam WS; Yoon SH; Song KH; Choe PG; Kim NJ; Jang IJ; Oh MD; Yu KS
Clin Infect Dis; 2012 Oct; 55(8):1080-7. PubMed ID: 22761409
[TBL] [Abstract][Full Text] [Related]
15. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age.
Shima H; Miharu M; Osumi T; Takahashi T; Shimada H
Pediatr Blood Cancer; 2010 Jul; 54(7):1050-2. PubMed ID: 20146339
[TBL] [Abstract][Full Text] [Related]
16. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy.
Baden LR; Katz JT; Fishman JA; Koziol C; DelVecchio A; Doran M; Rubin RH
Transplantation; 2003 Dec; 76(11):1632-7. PubMed ID: 14702539
[TBL] [Abstract][Full Text] [Related]
17. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O
Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925
[TBL] [Abstract][Full Text] [Related]
18. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J
Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709
[TBL] [Abstract][Full Text] [Related]
19. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis.
Choi SH; Lee SY; Hwang JY; Lee SH; Yoo KH; Sung KW; Koo HH; Kim YJ
Pediatr Blood Cancer; 2013 Jan; 60(1):82-7. PubMed ID: 22887791
[TBL] [Abstract][Full Text] [Related]
20. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
